Top news of the week: 28.12.2022.
Lexicon's AAK1 Inhibitor Disappoints in Phase II Postherpetic Neuralgia Study
Lexicon Pharmaceuticals’ LX9211 fell short of its primary efficacy endpoint, according to topline data from the Phase II RELIEF-PHN-1 study in post-herpetic neuralgia.
Why Bharat Biotech’s nasal vaccine can be a practical option
Being an intranasal vaccine, BBV154 may produce local antibodies in the upper respiratory tract which may have the potential to reduce infection and transmission
Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo Improvements were sustained for up to one year in ...
StockWatch: Investors Sing as Madrigal Shares Quadruple on Phase III Win
Madrigal Therapeutics shares quadruple in price after it aces a pivotal trial for its lead candidate in nonalcoholic steatohepatitis (NASH).
Ganymede Bio raises $12.75M for data platform
Ganymede Bio, the cloud infrastructure provider for the life sciences and manufacturing industries, has announced a $12.75M series A funding.
Henrietta Lacks' hometown will build statue of her to replace Robert E. Lee monument
A statue of the woman, whose cells were taken without her consent and became integral in several major medical breakthroughs, will be built in Roanoke, Va.
Bharat Biotech's nasal vaccine to be available on CoWIN app from today
Health Minister Dr Mansukh Mandaviya said that Bharat biotech nasal vaccine has been approved and will be added in CoWIN app.
Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine
Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo Improvements were sustained for up to one …